louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01900938: Comparison Between Continuous Infusion and Intermittent Bolus Injection of Propofol for Deep Sedation During ERCP
Official title: Comparison Between Continuous Infusion and Intermittent Bolus Injection of Propofol for Deep Sedation During Endoscopic Retrograde Cholangiopancreatography: a Prospective Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Biliary Tract Diseases
Pancreatic Diseases
Keywords: Cholangiopancreatography
Endoscopic Retrograde
Lead sponsor: Hanyang University
Sponsor class: OTHER
First posted: 2013-07-17
Enrollment: 210
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The aim of this study is to compare sedation efficiency, safety and satisfaction by both endoscopist, assistants, and the patients between continuous infusion and intermittent bolus injection of propofol for deep sedation during ERCP.

Detailed description: The patients undergone ERCP were randomly assigned to either continuous infusion of propofol (continuous group) or midazolam plus intermittent bolus injection of propofol (intermittent group) for deep sedation. In the continuous group, propofol was continuously administered via infusion pump and the doses were determined by sedation assistants monitoring the patients. In the intermittent group, a loading dose of 2 mg of midazolam and 0.4 mg/kg of propofol was initially injected and repeated bolus injection of 20 mg of propofol was followed according to patients' sedation level. Sedation related parameters (total dose of propofol, induction/recovery time, patients' cooperation) and adverse events during the procedure were evaluated. Satisfaction scores by endoscopist, assistant, and patients and difficulty scores of maintaining the sedation by assistants were also graded after the procedure.

Eligibility criteria: Inclusion Criteria:

* Patients undergone ERCP for biliary and pancreatic diseases

Exclusion Criteria:

* Comorbid conditions of ASA class 4-5
* Age under 18 years or over 90 years
* Pregnancy
* Past medication history of benzodiazepine or narcotics
* Known allergy to midazolam or propofol
* hypotension (systolic blood pressure \<90 mmHg), hypoxemia (SaO2 \<90%), or bradycardia (50/min) at baseline measurements

Primary outcomes:
measure: Satisfaction scores by endoscopist
timeFrame: 30 minutes after the procedure
Secondary outcomes:
measure: Adverse events for sedation
timeFrame: 1 day after the procedure
measure: Difficulty scores of maintaining the sedation
timeFrame: 30 minutes after the procedure
Other outcomes:
Locations:
city: Guri
country: Korea, Republic of
facility: Hanyang University Guri Hospital
state: Gyeonggi
Study officials:
affiliation: Hanyang University
name: Kyo-Sang Yoo
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01902238: EUS-guided Ethanol-lipiodol Ablation of Pancreatic Neuroendocrine Tumor: a Prospective Study
Official title: EUS-guided Ethanol-lipiodol Ablation of Pancreatic Neuroendocrine Tumor: a Prospective Feasibility and Long Term Outcome
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Efficacy
Safety
Feasibility
Keywords: neuroendocrine tumor
ethanol
endoscopic ultrasonography
Lead sponsor: Asan Medical Center
Sponsor class: OTHER
Collaborators: name: Dankook University
First posted: 2013-07-18
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The present study evaluate the safety and efficacy of EUS-guided ethanol-lipiodol ablation for the treatment of pancreatic NET

Detailed description: Pancreatic neuroendocrine tumor, including insulinoma, increasingly are being encountered in clinical practice. Management of pancreatic NET is challenging because most are asymptomatic but may have malignant potential, and surgical resection of pancreatic neoplasm is associated with substantial morbidity of 20%-40% and a mortality rate of 2%. Management strategy needs to be individualized, applying a risk-benefit analysis to each patient. Recently, pancreatic tissue ablation by EUS-guided injection of ethanol or other chemotherapeutic agents can be performed safely, with few procedure-related complications. Levy et al. demonstrated that EUS-guided ethanol ablation for insulinoma was both safe and feasible, and symptomatic improvement was achieved in 8 of 8 patients (100%). However, previous study have included only a small number of patients and evaluated only short-term outcomes. In addition, lipiodol permits the drug to concentrate in the tumor. To obtain an embolic effect and prevent washout of the ethanol, ethanol/lipiodol mixture is administered into the tumor. The present study evaluate the safety and efficacy of EUS-guided ethanol-lipiodol ablation for the treatment of pancreatic NET

Eligibility criteria: Inclusion Criteria:

* Pancreas NET(including insulinoma) \< 2cm in diameter
* Poor surgical candidate (involving the head of the pancreas or multifocal NET, advanced comorbidity, age \>75 years of age)
* Refuse to surgery

Exclusion Criteria:

* Younger than 18 years of age
* Coagulopathy (INR \>1.5, Platelet \<50,000)
* Evidence of active pancreatitis
* Inability to safely undergo EUS
* Refuse to participate

Primary outcomes:
measure: Number of participants with treatment response
timeFrame: more than 3 years after procedure
Secondary outcomes:
measure: The number of participants with post-procedure adverse events
timeFrame: until 3 months after procedure
Other outcomes:
measure: Technical feasibility
timeFrame: at the time of procedure
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
Study officials:
affiliation: Asan Medical Center, Seoul, Korea, Republic of
name: Do Hyun Park, MD, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT06268938: Outcomes of Mastoid Obliteration Canal Wall Down Tympanomastoidectomy in Cholesteatoma Surgery
Official title: Outcomes of Mastoid Obliteration Canal Wall Down Tympanomastoidectomy in Cholesteatoma Surgery
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Cholesteatoma
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2024-02-20
Enrollment: 4
Sex: ALL
Minimum age (years): 5
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Randomised study to evaluate the outcomes of mastoid cavity obliteration by muscle versus bone in canal wall down tympanomastoidectomy in cholesteatoma surgery

Detailed description: Regarding discharge Time of epithelizqtion Hearing outcomes Quality of life

Eligibility criteria: Inclusion Criteria:

* all patients who have extensive or recuutrent cholesteatoma undergoing canal wall down tympanomastoidectomy

Exclusion Criteria:

* not willing for surgery
* Malignancy

  * Patients with intracranial complication
* Residual cholesteatoma

Primary outcomes:
measure: Size of mastoid cavity in mm
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Assiut university hospital
city: Assiut
country: Egypt
facility: Rehab Abd Elal Mohammed
Study officials:
References:
citation: Mehta RP, Harris JP. Mastoid obliteration. Otolaryngol Clin North Am. 2006 Dec;39(6):1129-42. doi: 10.1016/j.otc.2006.08.007.
citation: Khalil HS, Windle-Taylor PC. Canal wall down mastoidectomy: A long term commitment to the outpatients? BMC Ear Nose Throat Disord. 2003 Sep 4;3(1):1. doi: 10.1186/1472-6815-3-1.
citation: Illes K, Meznerics FA, Dembrovszky F, Fehervari P, Banvolgyi A, Csupor D, Hegyi P, Horvath T. Mastoid Obliteration Decreases the Recurrent and Residual Disease: Systematic Review and Meta-analysis. Laryngoscope. 2023 Jun;133(6):1297-1305. doi: 10.1002/lary.30413. Epub 2022 Sep 28.
citation: Krol B, Cywka KB, Skarzynska MB, Skarzynski PH. Mastoid obliteration with S53P4 bioactive glass after canal wall down mastoidectomy: Preliminary results. Am J Otolaryngol. 2021 Mar-Apr;42(2):102895. doi: 10.1016/j.amjoto.2020.102895. Epub 2021 Jan 5.
citation: Weiss NM, Bachinger D, Botzen J, Grossmann W, Mlynski R. Mastoid cavity obliteration leads to a clinically significant improvement in health-related quality of life. Eur Arch Otorhinolaryngol. 2020 Jun;277(6):1637-1643. doi: 10.1007/s00405-020-05881-4. Epub 2020 Mar 6.
Clinical trial NCT02089438: DPP-4 Inhibition, Incretins and Islet Function
Official title: Comparison of Three DPP-4 Inhibitors on 24 Hour Blood Glucose, Incretin Hormones and Islet Function in Patients With Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Type 2 Diabetes
Lead sponsor: Lund University
Sponsor class: OTHER
First posted: 2014-03-17
Enrollment: 24
Sex: ALL
Minimum age (years): 40
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Hypothesis is that DPP-4 inhibition affects glucose levels through changes in incretin and islet hormones. The study examines this in relation to breakfast, lunch and dinner over an entire 24h study period by the use of three different DPP-4 inhibitors and placebo.

Detailed description: The study is a single-center study with a cross-over design to examine glycemia, incretin hormones and islet hormones over a 24h study period with standardized breakfast, lunch and dinner after administration of placebo, saxagliptin, vildagliptin or sitagliptin.

Eligibility criteria: Inclusion Criteria:

* • Caucasian men or women with type 2 diabetes diagnosed according to ICD10 at time of inclusion

  * Ongoing treatment with life style adjustment including diet and exercise regimen together with metformin as oral antidiabetic . Metformin therapy should be stable the last three months
  * Age 40-75 years
  * HbA1c 52-80 mmol/mol (inclusive)
  * BMI: 20-40 kg/m2
  * Written informed consent has been given
  * Capability and willingness to participate in the whole study

Exclusion Criteria:

* • Liver disease (K70-77 in ICD10) or liver enzymes three times above upper reference range

  * Diabetic nephropathy (GFR \< 30 mL/min/1.73 m2 or albuminuria) or other causes of renal disease
  * Proliferative diabetic retinopathy
  * Treatment with any glucose-lowering medication except metformin
  * Previous myocardial infarction, coronary heart disease or instable angina pectoris in the last 6 months.
  * Symptomatic heart failure (NYHA class II-III)
  * Previous surgery on the gastrointestinal tract
  * Larger surgical intervention during the last 12 weeks
  * Female subject who are pregnant or breast feeding
  * Women of child bearing potential not using a highly effective method of birth control
  * Treatment with oral steroids, thiazide diuretics, digoxin or growth hormone
  * Hypersensitivity to the active substances of to any of the excipients
  * Participation in another study the last 4 weeks
  * Smoker
  * Paracetamol intolerance

Primary outcomes:
measure: Postprandial glucose
timeFrame: 180 min
Secondary outcomes:
measure: Postprandial insulin and glucagon
timeFrame: 180 min
measure: Postprandial glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)
timeFrame: 180 min
Other outcomes:
Locations:
city: Lund
country: Sweden
facility: Clinical Research Department
Study officials:
affiliation: Lund University
name: Bo Ahrén, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04014738: The Prognostic Value of Human Papilloma Virus in Nasopharyngeal Carcinoma
Official title: The Prognostic Value of Human Papilloma Virus in Nasopharyngeal Carcinoma
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Nasopharyngeal Carcinoma
Lead sponsor: Rambam Health Care Campus
Sponsor class: OTHER
First posted: 2019-07-10
Enrollment: 100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients diagnosed with nasopharyngeal carcinoma

Brief summary: It is well established that HPV infection has a casual and is a prognostic factor in several cancer types, including oropharynx. We wish to examine if HPV infection has a prognostic significance in nasopharyngeal carcinoma.


Eligibility criteria: Inclusion Criteria:

* nasopharyngeal carcinoma patients treated in our institute between 2008-2018

Exclusion Criteria:

* missing clinical data
* 2nd Head and neck primary cancer
* very locally advanced or distant metastatic nasopharyngeal carcinoma
* Prior radiation therapy to the head and neck region

Primary outcomes:
measure: Overall survival
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Rambam medical center
Study officials:
affiliation: Rambam Health Care Campus
name: Eran S Fridman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05460338: Vitamin D, Oxidative Stress and Inflammation in Hemodialysis
Official title: Effect of Oral Vitamin D on Oxidative Stress and Inflammation in Hemodialysis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Oxidative Stress
Inflammation
Vitamin D Deficiency
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2022-07-15
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Vitamin D deficiency is now considered a global problem in general population, but it seemed to be more prominent in chronic kidney disease (CKD) patients, especially those on regular hemodialysis. Being a key regulator in mineral metabolism, there's also emerging evidences linking vitamin D deficiency with inflammation and oxidative stress, which are both recognized as constant threats to cardiovascular outcomes in hemodialysis patients.

It's prospective, randomized trial that's carried out to evaluate the effect of weekly versus, monthly oral cholecalciferol, on vitamin D (25(OH)D) levels, oxidative stress markers, inflammatory markers and secondary hyperparathyroidism in hemodialysis patients. Fifty eligible hemodialysis patients were randomly assigned to either Group A (Oral 50.000IU Cholecalciferol, once weekly) or Group B (Oral 200.000IU Cholecalciferol, once monthly), for 3 months. Serum levels of (25(OH)D), serum malondialdehyde (MDA), serum superoxide dismutase (SOD), serum high sensitive (hsCRP), calcium, phosphorus, and intact parathormone (iPTH) levels, were all assessed at baseline and at the end of the study


Eligibility criteria: Inclusion Criteria:

* Male or female patients aged between 18-70 years, on maintenance hemodialysis for a duration of 3 months or more, in a stable clinical condition (no hospitalization in the previous 3 months), with serum vitamin D levels of \< 30 ng/ml.

Exclusion Criteria:

* Patients with hypersensitivity to cholecalciferol, ongoing cholecalciferol therapy, liver failure, digestive malabsorption disease, being participating in an another clinical trial within the past 4 weeks, females that are pregnant or breastfeeding, or patients being judged to be unsuitable to be enrolled by the attending physician.

Primary outcomes:
measure: (25(OH)D)
timeFrame: 3 months
Secondary outcomes:
measure: serum sodium dismutase (SOD)
timeFrame: 3 months
measure: intact parathyroid hormone (iPTH)
timeFrame: 3 months
measure: serum Malondialdehyde (MDA)
timeFrame: 3 months
measure: serum high sensitive C-reactive Protein (HsCRP)
timeFrame: 3 months
measure: serum calcium level (Ca)
timeFrame: 3 months
measure: serum phosphate level (PO4)
timeFrame: 3 months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams University Hospital
Study officials:
References:
Clinical trial NCT01997138: Effects of Intraarticular IL1-Ra on Pain and Inflammatory Mediators After Knee Arhroscopy
Official title: Effects of Intraarticular IL1-Ra on Pain and Inflammatory Mediators After Knee Arhroscopy -a Double Blind, Placebo Controlled Study Using Microdialysis Technique
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Knee Injuries
Keywords: pain, inflammation, surgery
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
Collaborators: name: University of Oslo
name: Lovisenberg Diakonale Hospital
First posted: 2013-11-27
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This project investigates the relation between acute pain and local inflammation. Pain reported by the patients for knee arthroscopy are compared with local changes in inflammatory mediators by using microdialysis technique. Patients with moderate-to-severe pain are included in a randomized placebo-controlled trial of anakinra given intra-articularly.

Detailed description: The effects of the recombinant IL-1 receptor antagonist anakinra both on acute pain and post operative inflammation will be evaluated. On inclusion, pain intensity will be measured on a five-point verbal rating scale (0= no pain, 1=mild pain, 2=moderate pain, 3=severe pain, and 4=intolerable pain), and on a visual analogue scale (0-100mm). VAS scale will be repeated at 20, 40, 60, 80, 100, 120, 140, 160, 180 and 200 minutes after inclusion / intervention. The patients will also rate pain intensity during a 5 meters walk at 200 minutes (evoked pain). The patient will rate pain at rest and evoked pain 24, 48 and 72 h after intervention.

Eligibility criteria: Inclusion Criteria:

1. Otherwise healthy patients (ASA 1 and 2) undergoing knee arthroscopy in general anaesthesia.
2. Being informed about and willing to participate in the study -

Exclusion Criteria:

1. Pregnancy or lactation. Fertile women will be asked if they may be pregnant, and offered a pregnancy test if there is doubt.
2. Established osteoarthritis or synovitis
3. Known intolerance to anakinra
4. Kidney failure (Creatinine clearance \<30ml/min)
5. History of frequent infectious diseases or immunodeficiency
6. Heart failure
7. History of drug -or alcohol abuse
8. Participation in other synchronous clinical trials
9. Perioperative steroid treatment, perioperative paracetamol (12 hrs), NSAIDs (24 hrs) or COX2-inhibitors (48 hrs).
10. Use of tourniquet for bloodless field
11. Strong preoperative pain (VRS ≥3)
12. Intolerable postoperative pain (VRS=4)

Primary outcomes:
measure: Pain relief
timeFrame: 72h
Secondary outcomes:
measure: Resuce analgesic drug consumption
timeFrame: 72h
Other outcomes:
measure: Side effects
timeFrame: 72h
Locations:
city: Oslo
country: Norway
facility: Lovisenberg Diakonal Hospital
Study officials:
References:
Clinical trial NCT00010738: Effects of Meditation on Mechanism of Coronary Heart Disease
Official title: Effects of Meditation on Mechanism of Coronary Heart Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Coronary Heart Disease
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH)
Sponsor class: NIH
First posted: 2001-02-05
Enrollment: 145
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Primary purpose: TREATMENT

Brief summary: To study the effects of Transcendental Meditation on Coronary Heart Disease

Detailed description: Recent advances in our understanding of the pathophysiology of acute cardiac events - specifically, identification of the roles that arterial vasomotor dysfunction and autonomic nervous system imbalances play in the pathophysiologic cascade during such acute events - provides a platform for new mechanistic investigation of the interplay of psychosomatic stress and CHD (coronary heart disease). Preliminary evidence further suggests that Complementary and Alternative Medicine (CAM) practices, such as the Transcendental Meditation (TM) technique, can not only reduce stress but also reduce acute cardiac events in patients with CHD. Based on these and related data, we propose a randomized, blinded, controlled study of the effects of one CAM practice, the TM technique, compared to a control group, on the primary outcomes of (1) arterial vasomotor dysfunction (brachial artery reactivity); (2) autonomic nervous system imbalances (heart rate variability); (3) transient myocardial ischemia (ST-segment depression); and (4) the secondary outcomes of psychological stress and quality of life (anger, hostility, anxiety, depression, perceived health, disease-specific symptoms, and life stress/social resources).

Eligibility criteria: Inclusion Criteria:

* Able to attend training sessions and meetings
* Local residence

Exclusion Criteria:

* Comorbid disease precluding survival in group
* MI, unstable angina, CABG or PTCA within last three months.
* Cognitive/psychological/substance abuse impairment
* Atrial fibrillation, predominant pacemaker rhythm or significant conduction system disease
* Significant valvular heart disease
* Class III or IV heart failure
* Renal failure
* Participating in a formal stress management program
* Participation in another trial

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Preventive and Rehabilitative Cardiac Center
state: California
Study officials:
affiliation: Preventive and Rehabilitative Cardiac Center
name: C. Noel Bairey Merz, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05297838: Stationary Bike Use During Ice Bath and Virtual Reality
Official title: The Utilization of a Stationary Bike During Ice Bath While Using Virtual Reality (VR) to Determine Overall Pain Reduction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain
Keywords: Ice bath
Virtual Reality
Stationary Bike
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2022-03-28
Enrollment: 151
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the effectiveness of different technologies, in particular Virtual Reality, inclusive of passive content, active content, cognitive load modulation, and positive encouragement coaching to increase the pain threshold as assessed by immersing a hand in ice water while utilizing a stationary bike.


Eligibility criteria: Inclusion Criteria:

* Greater than 18 years of age
* English speaking
* Hearing intact

Exclusion Criteria:

* Patients who do not consent
* Are currently taking beta blockers or other chronotropic heart medication(s)
* Have a history of severe motion sickness
* Currently have nausea
* Currently experiencing seizures
* Are clinically unstable

Primary outcomes:
measure: Self-Reported Pain Scores (Ice Bath vs VR Bike)
timeFrame: Duration of ice bath (approximately 0 - 4 minutes)
measure: Sympathetic Activation (VR vs VR Bike)
timeFrame: Duration of ice bath (approximately 0 - 4 minutes)
Secondary outcomes:
measure: Pain Tolerance (Ice Bath vs VR Bike)
timeFrame: Duration of ice bath (approximately 0 - 4 minutes)
measure: Sympathetic Activation (Ice Bath vs VR Bike)
timeFrame: Duration of ice bath (approximately 0 - 4 minutes)
measure: Self-Reported Pain Scores (VR vs VR Bike)
timeFrame: Duration of ice bath (approximately 0 - 4 minutes)
measure: Pain Tolerance (VR vs VR Bike)
timeFrame: Duration of ice bath (approximately 0 - 4 minutes)
Other outcomes:
Locations:
city: Palo Alto
country: United States
facility: Lucile Packard Children's Hospital Stanford
state: California
Study officials:
References: